C12N 2760/18762
By genetic engineering
Official title: by genetic engineering
C12N2760/18762 (By genetic engineering) appears on 9 US grants and 12 published applications in this corpus.
Search patents in C12N- Granted patents
- 9
- Published applications
- 12
- Assignees
- 10
- Inventors
- 18
- Latest grant
- 8 Jun 2021
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2000 | 1 | 0 |
| 2001 | 0 | 0 |
| 2002 | 0 | 1 |
| 2003 | 1 | 1 |
| 2004 | 0 | 2 |
| 2005 | 1 | 0 |
| 2006 | 0 | 0 |
| 2007 | 0 | 0 |
| 2008 | 0 | 1 |
| 2009 | 0 | 0 |
| 2010 | 1 | 0 |
| 2011 | 1 | 1 |
| 2012 | 0 | 0 |
| 2013 | 1 | 1 |
| 2014 | 0 | 1 |
| 2015 | 0 | 1 |
| 2016 | 0 | 0 |
| 2017 | 2 | 1 |
| 2018 | 0 | 0 |
| 2019 | 0 | 1 |
| 2020 | 0 | 0 |
| 2021 | 1 | 0 |
| 2022 | 0 | 1 |
By publication year. Applications have been published since 2001.
Recent patents
- Recombinant mumps virus vaccine8 Jun 2021US 11,027,008 B2The United States of America, as represented by the Secretary, Department of Health and Human Services
- Vaccine prepared utilizing human parainfluenza virus type 2 vector4 Jul 2017US 9,695,444 B2Biocomo Inc.
- Recombinant mumps virus vaccine16 May 2017US 9,649,371 B2University of Georgia Research Foundation, Inc.
- Recovery of recombinant human parainfluenza virus type 2 (HYPIV2) from cDNA and use of recombinant HPIV2 in immunogenic compositions and as vectors to elicit immune responses against PIV and other human pathogens5 Feb 2013US 8,367,074 B2The United States of America, as represented by the Secretary, Department of Health and Human Services
- Recovery of recombinant human parainfluenza virus type 2 (HPIV2) from CDNA and use of recombinant HPIV2 in immunogenic compositions and as vectors to elicit immune responses against PIV and other human pathogens5 Apr 2011US 7,919,301 B2The United States of America, as represented by the Secretary, Department of Health and Human Services
- Recombinant mumps virus vaccine expressing genotype g fusion and hemagglutinin-neuraminidase proteins27 Jan 2022US 2022/0023413 A1The U.S.A., as represented by the Secretary, Department of Health and Human Services
- Recombinant mumps virus vaccine18 Jul 2019US 2019/0216918 A1University of Georgia Research Foundation, Inc.
- Recombinant mumps virus vaccine17 Aug 2017US 2017/0232098 A1University of Georgia Research Foundation, Inc.
- Vaccine prepared utilizing human parainfluenza virus type 2 vector19 Nov 2015US 2015/0329874 A1Biocomo Inc.
- Recombinant mumps virus vaccine9 Jan 2014US 2014/0010840 A1University of Georgia Research Foundation, Inc.
Most cited
By later US patents
- Recovery of recombinant human parainfluenza virus type 2 (HYPIV2) from cDNA and use of recombinant HPIV2 in immunogenic compositions and as vectors to elicit immune responses against PIV and other human pathogens4US 8,367,074 B2The United States of America, as represented by the Secretary, Department of Health and Human Services · 2013
- Vaccine against mumps containing a Jeryl-Lynn virus strain2US 6,024,962 ASmithKline Beecham Biologicals s.a. · 2000